<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372787">
  <stage>Registered</stage>
  <submitdate>23/04/2017</submitdate>
  <approvaldate>2/05/2017</approvaldate>
  <actrnumber>ACTRN12617000639325p</actrnumber>
  <trial_identification>
    <studytitle>Artemisia Annua in the management of Asthma</studytitle>
    <scientifictitle>A randomized double blinded controlled trial on the use of Artemisia Annua in the management of stable Asthmatics</scientifictitle>
    <utrn>U1111-1195-8612 </utrn>
    <trialacronym>AAMA</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1 - Artemisia Annua 175mg twice a day oral capsule for 22 weeks
Arm 2 - Placebo - Rice Flour twice a day oral capsule for 22 weeks
Capsule return at the completion of the trial will be requested to monitor adherence
</interventions>
    <comparator>Control treatment - Rice Flour capsule, 1 capsule twice a day</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Peak Expiratory flow rate level as measured with a peak flow meter</outcome>
      <timepoint>8 weeks, 22 weeks post trial commencement.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in pulmonary function levels as measured with desktop spirometry.</outcome>
      <timepoint>8 weeks and 22 weeks post trial commencement.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Quality of life scores as measured by the Asthma Quality of Life Questionnaire</outcome>
      <timepoint>8 weeks and 22 weeks post trial commencement.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age over 12 years
Stable Asthma as defined by pulmonary function testing showing a 10% or greater increase in pulmonary function following bronchodilator administration.
</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Smoking history over 10 years
inability to provide informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>This is a pilot study and as such there is no basis for sample size calculations. The data will be analysed with a simple t-test score.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/07/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>1/07/2018</anticipatedenddate>
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Waikato</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Stuart Armstrong</primarysponsorname>
    <primarysponsoraddress>Anglesea Sports Medicine
7-9 Thackeray street
Hamilton
New Zealand
3204
</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Dr Stuart Armstrong</fundingname>
      <fundingaddress>Anglesea Sports Medicine
7-9 Thackeray street
Hamilton
New Zealand
3204</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress>none</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>During trials on Artemisia Annuas use for malarial treatment anecdotal evidence emerged of its beneficial effect on inflammatory processes including asthma. This has led to further studies specifically looking its anti-inflammatory role. It has been shown to have a direct effect on human bronchial epithelial cells and a study looking at its effect on a mouse allergic asthma model was very promising. 
Previous studies have shown the anti-inflammatory potential of Arthrem in vitro and previous animal studies have shown a benefit of the active ingredient Artemisia annua in the treatment of asthma. The mechanism of action of this drug is thought to be downregulation of the inflammatory cascade in the airways of patients with inflammatory asthma, but the exact mechanism remains undetermined.
This study is a randomized double blinded randomized control trial looking to compare asthma control in 2 groups. One group will be given the herbal supplement Artemisia annua 175mg twice a day and the other will be given a placebo containing rice flour. It will involve participants over the age of 12 with a less than 10 year smoking history with a diagnosis of stable asthma. It will last 6 months and involve the comparison of asthma control as measured by peak flow, pulmonary function tests and a questionnaire.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
Health and Disability Ethics Committees
PO Box 5013
Wellington 6140</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/06/2017</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Stuart Armstrong</name>
      <address>Anglesea Sports Medicine
7-9 Thackeray Street
Hamilton
New Zealand 3204</address>
      <phone>+64 211492438</phone>
      <fax />
      <email>drsarmstrong@gmail.com</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Stuart Armstrong</name>
      <address>Anglesea Sports Medicine
7-9 Thackeray Street
Hamilton
New Zealand 3204</address>
      <phone>+64 211492438</phone>
      <fax />
      <email>drsarmstrong@gmail.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Stuart Armstrong</name>
      <address>Anglesea Sports Medicine
7-9 Thackeray Street
Hamilton
New Zealand 3204</address>
      <phone>+64 211492438</phone>
      <fax />
      <email>drsarmstrong@gmail.com</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Stuart Armstrong</name>
      <address>Anglesea Sports Medicine
7-9 Thackeray street
Hamilton
New Zealand
3204</address>
      <phone>+64 211 492 438</phone>
      <fax />
      <email>drsarmstrong@gmail.com</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>